RxDoctor Payments Data

Vicky Pai, MD

Ophthalmology · Glendora, CANPI 1740485895

Payments from drug & device makers

$14,155in general payments, 2019–2025

Across 332 payments — averaging $42.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Shire North American Group Inc$2K
  • Alcon$2K
  • Sun Pharmaceutical Industries Inc.$986
  • Novartis$654
  • Sight Sciences, Inc.$576
  • plus $4K from 22 others

What the payments were for

  • Travel & lodging$2693%
  • Food & beverage$9,11795%
  • Gifts$621%
  • Other$1602%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,155 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$252,609
Medicare patients
838
Services billed
2,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine69$76,734
RocklatanNetarsudil Mesylat/Latanoprost35$20,228
IlevroNepafenac50$18,261
CequaCyclosporine12$16,401
LumiganBimatoprost22$15,825
Cyclosporine22$10,182
Cosopt PfDorzolamide/Timolol/Pf12$4,696
Dorzolamide-TimololDorzolamide/Timolol/Pf17$4,004
Prednisolone Acetate108$3,726
Difluprednate40$3,040
XalatanLatanoprost11$2,588
TafluprostTafluprost/Pf15$2,284
MoxifloxacinMoxifloxacin Hcl121$2,135
Timolol Maleate52$1,680
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat82$1,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$3,547$92,55991 claims
Aerie Pharmaceuticals, Inc.Rocklatan$245$20,22835 claims
NovartisIlevro$654$18,26150 claims
Sun Pharmaceutical Industries Inc.Cequa$986$16,40112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Glendora

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →